DECADRON (dexamethasone) by Merck & Co. is clinical pharmacology naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Approved for multiple myeloma, postoperative nausea and vomiting. First approved in 1960.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
DECADRON (dexamethasone) is a synthetic glucocorticoid approved in 1960 that works through potent anti-inflammatory mechanisms by modifying immune responses and metabolic effects. It is indicated for multiple myeloma and postoperative nausea and vomiting as an oral elixir formulation. Unlike hydrocortisone, dexamethasone lacks sodium-retaining properties at equipotent anti-inflammatory doses.
As a near-LOE product with minimal linked job activity, this represents a mature, stable portfolio asset with limited commercial expansion opportunities.
CLINICAL PHARMACOLOGY Naturally occurring glucocorticoids, (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs, including dexamethasone, are primarily used for their potent…
Worked on DECADRON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on DECADRON offers limited career growth opportunities given its mature lifecycle status and lack of linked job postings. This role is suited for professionals focused on portfolio maintenance, cost optimization, and defensive market positioning rather than innovation or commercial expansion.